Guardant Health® and COTA Partner to Explore the Costs, Benefits, and Barriers of Genotyping Patients with Advanced Lung Cancer with a Non-invasive Liquid Biopsy NEW YORK, March 15, 2016 (GLOBE NEWSWIRE) -- COTA Inc. and Guardant Health have partnered to provide new insights into the barriers to obtaining genomic profiling of driver mutations among patients...